Sense Biodetection, Abingdon, UK, has accelerated its program to launch the Veros SARS-CoV-2 assay, an instrument-free, point-of-care molecular diagnostic for SARS-CoV-2, the coronavirus responsible for the covid-19 pandemic. Sense is partnering with Phillips Medisize, Hudson, Wis, to scale-up production of the test in order to meet the growing demand for rapid diagnostics.
The Veros SARS-CoV-2 assay is a simple disposable test that uses a nasal swab sample to give a result in less than 10 minutes without the need for any instrumentation. The test is fully self-contained and can be widely distributed to wherever it is needed.
“Our Veros covid-19 test product can allow infected patients to be isolated sooner whilst providing reassurance to uninfected individuals, including healthcare workers, that they can return to work without infecting others,” says Harry Lamble, chief executive officer at Sense. “Due to its flexibility, speed, and accuracy, the test can be deployed for rapid patient triage within hospitals as well as primary care practices, pharmacies, and community centers, and even distributed for use by individuals in isolation who suspect they may have covid-19.”
For more information, visit Sense Biodetection.
